90780-52-2

Usage

Uses

Used in Pharmaceutical Industry:
(+/-)17-HDOHE is used as a pharmaceutical agent for its potential anti-inflammatory and immunomodulatory properties. It has been found to modulate the production of pro-inflammatory and anti-inflammatory mediators, making it a promising candidate for the treatment of inflammatory diseases.
Used in Neuroprotection:
(+/-)17-HDOHE is used as a neuroprotective agent due to its ability to protect neurons from oxidative stress and inflammation. It has been shown to reduce neuronal damage and improve cognitive function in various neurodegenerative diseases.
Used in Cardiovascular Health:
(+/-)17-HDOHE is used as a cardiovascular health promoter due to its potential to improve blood flow, reduce inflammation, and lower blood pressure. It may help in the prevention and treatment of cardiovascular diseases.
Used in Skin Care Industry:
(+/-)17-HDOHE is used as an ingredient in skin care products for its anti-inflammatory and skin barrier strengthening properties. It may help in reducing skin inflammation, improving skin hydration, and promoting skin health.
Used in Nutritional Supplements:
(+/-)17-HDOHE is used as a nutritional supplement to support overall health and well-being. It may help in maintaining a healthy balance of omega-3 fatty acids in the body, which is essential for various physiological functions.

InChI:InChI=1/C22H32O3/c1-2-3-15-18-21(23)19-16-13-11-9-7-5-4-6-8-10-12-14-17-20-22(24)25/h3,5-8,11-16,19,21,23H,2,4,9-10,17-18,20H2,1H3,(H,24,25)/b7-5-,8-6-,13-11-,14-12-,15-3-,19-16+

Upstream product

• 6217-54-5 docosahexaenoic acid 
• 1233715-28-0 17-oxo-4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid 
• 92693-03-3 (17S)-HDHA 

Relevant academic research and scientific papers

First total synthesis of the anti-inflammatory and pro-resolving lipid mediator 16(R),17(S)-diHDHA

The first total synthesis of the anti-inflammatory and pro-resolving lipid mediator 16(R),17(S)-diHDHA, derived from docosahexaenoic acid (DHA), and its 16-epimer have been achieved. Two synthetic approaches are described for the synthesis of 16(R),17(S)-diHDHA. The first strategy started from DHA and used an enzymatic reaction, a vanadium catalyzed allylic epoxidation and a base-promoted epoxide isomerization. The second approach utilized a chiral pool strategy starting from 2-deoxy-D-ribose to establish the chiral centers; Wittig reactions, mild acetonide cleavage and ester hydrolysis were the key steps in the synthesis.

14-HYDROXY-DOCOSAHEXAENOIC ACID COMPOUNDS

The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogues, their preparation, isolation, identification, purification and uses thereof.

OXYLIPINS FROM LONG CHAIN POLYUNSATURATED FATTY ACIDS AND METHODS OF MAKING AND USING THE SAME

Disclosed are novel oxylipins, referred to herein as docosanoids, that are derived from C22 polyunsaturated fatty acids, and method of making and using such oxylipins. Also disclosed is the use of docosapentaenoic acid (C22:5n-6) (DPAn-6), docosapentaenoic acid (C22:5n-3) (DPAn-3), and docosatetraenoic acid (DTAn-6: C22:4n-6) as substrates for the production of novel oxylipins, and to the oxylipins produced thereby. Also disclosed is the use of DPAn-6, DPAn-3, DTAn-6, and/or the oxylipins derived therefrom, and/or novel docosanoids derived from the structures of C22 fatty acids, in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. The invention also relates to novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of LCPUFA-derived oxylipins, and particularly, docosanoids.